Combined use of TPO-RAs with low-dose anti-CD20 antibody
IIT2020034
Phase 3 small_molecule active
Quick answer
Combined use of TPO-RAs with low-dose anti-CD20 antibody for Immune Thrombocytopenia (ITP) is a Phase 3 program (small_molecule) at China SXT Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Program details
- Company
- China SXT Pharmaceuticals
- Indication
- Immune Thrombocytopenia (ITP)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active